非小细胞肺癌不同组织标本中P16基因的PCR-SSCP分析  

Analysis of P16 gene for different tumor tissue in non-small cell lung cancer by PCR-SSCP

作　　者：包国良[1] 冯久贤[1] 董强刚[1] 沙慧芳[1] 江晓丰[1] 黄进肃[1] 廖美琳[1] 

机构地区：[1]上海市胸科医院,上海市胸部肿瘤研究所

出　　处：《临床肿瘤学杂志》2002年第1期1-4,共4页Chinese Clinical Oncology

基　　金：上海市医学发展基金重点项目资助 (99ZO 110 0 1)

摘　　要：目的 :研究非小细胞肺癌 (NSCLC)不同来源与病理分期类型的组织标本中P16基因表达的相互关系。方法 :应用PCR -SSCP方法 ,检测 2 8例手术标本、2 1例支气管镜活检及 2 7例恶性胸水NSCLC患者中P16基因的表达。结果 :2 8例Ⅰ期手术标本中 8例P16基因发生改变 (2 8 6 % ) ,其中 5例纯合性缺失 ,3例点突变 ;2 1例支气管镜活检中 ,8例P16基因发生改变 (38 1% ) ,其中 3例纯合性缺失 ,5例点突变 ;2 7例恶性胸水标本中 ,17例P16基因发生改变 (6 3 0 % ) ,其中 16例纯合性缺失 ,1例点突变。恶性胸水患者的P16基因改变率与Ⅰ期手术标本、支气管镜活检相比较 ,有显著性差异 (分别为P <0 0 1、P<0 0 0 5 )。在 76例NSCLC中 ,Ⅰ期患者的P16基因改变率为 30 0 % (9/ 30 ) ,Ⅱ期患者为 5 0 % (2 / 4 ) ,Ⅲ期患者为 5 1 6 % (16 /31) ,Ⅳ期患者为 5 4 5 % (6 / 11)。Ⅰ期患者的P16基因改变率与Ⅱ、Ⅲ、Ⅳ期患者相比较 ,均有显著性差异 (P <0 0 5 )。腺癌患者的P16基因改变率为 4 5 0 % (18/ 4 0 ) ,鳞癌患者为 4 2 3% (11/ 2 6 ) ,而腺鳞癌混合型为 4 0 0 % (4/ 10 ) ,经统计学分析 ,三者无显著性差异。而鳞癌患者的P16基因突变率为 2 3 1% (6 / 2 6 ) ,腺癌患者为 7 5 % (3/ 4 0 ) ,二者有显著性差异 (P <0Objective:To investigate relationship of the expression of P16 gene exon 2 in the different tumor tissue with pathological stages and types of non-small cell lung cancer(NSCLC).Methods:Expression of P16 gene were determined by PCR-SSCP method in 28 operate-resected,21 fiber-bronchoscope biopsy and 27 malignant pleural effusion patients with the NSCLC.Results:Eight of 28(28.6%)operate-resected tumor were alteration of P16 gene,and 5 were homozygous deletions and 3 were point mutations.Eight of 21(38.1%)biopsy from fiber-bronchoscope were alteration of P16 gene,and 3 were homozygous deletions and 5 were point mutations.Seventeen of 27(63.0%)malignant pleural patients were alteration of P16 gene,and 16 were homozygous deletions and 1 was point mutation.Altered rate of P16 gene from malignant pleural effusion patients had significantly been increased,compared with that from operate-resected,fiber-bronchoscope patients ( P < 0.005 , P <0.01).In the 76 NSCLC,the frequencies of P16 gene alteration were approximately 43.4%.Nine of 30(30%)the patients with stage Ⅰ of the disease,two of 4(50%)were stage Ⅱ,sixteen of 31(51.6%)were stage Ⅲ,six of 11(54.5%)were stage Ⅳ.Frequency of P16 gene alteration of the patients with stage Ⅰ had significantly decreased,compared with those of stage Ⅱ,stage Ⅲ,stage Ⅳ( P <0.05).Eighteen of 40(45.0%)were frequency of P16 gene alteration from adenocarcinoma disease,eleven of 26(42.3%)were from squamous carcinoma,four of 10(40.0%)were from mixed adeno-squamous carcinoma.These frequency of P16 gene had not significant difference by statistical analysis,but 6 of 26(23.1%)of frequency of P16 gene mutation from squamous carcinoma had significantly higher 3 of 40(7.5%)of that from adenocarcinoma( P <0.01).Conclusion:These results indicate that frequency of P16 gene alteration had not been significantly associated with pathological types of the tumor,but frequency of P16 gene mutation from patients with squamous carcinoma had significantly higher than from patients with ad

关 键 词：肺肿瘤 抑癌基因 PCR-SSCP P16基因 非小细胞肺癌 病因 

分 类 号：R734.202[医药卫生—肿瘤]